Through its four integrated service divisions, the Facility Maintenance and Operafion Core (FAC-OPS) provides high containment operational management monitoring and oversight;routine facilities preventive maintenance and upkeep of the GNL physical plant that supports the entire facility including the high containment space and a preventative maintenance plan for all BSL4 equipment and systems;non-routine emergency repairs of BSL4 equipment and systems;and specialized training for facilities personnel working in and around BSL4 space and associated building systems. This core ensures continuous scientific support by combining management of base science support and high containment operafional systems thus better maintaining synchrony with scientific program needs. Funcfional safety and security is ensured by independent oversight by autonomous entifies from other cores that have supervisory responsibilifies (biosafety, security, GMP&GLP compliance). The scientific, engineering and biosafety training acfivifies within the GNL are interiinked with a succession of training experiences at increasing levels of biosafety for individuals with no previous experience within biocontainment. The progression of scientists and support staff through these levels is an important funcfion of the training mission of the GNL which incorporates all levels of biosafety including BSL4. The amalgamafion of science support, biocontainment and engineering services gives scientific and engineering staff increased opportunities to understand the integrated nature of such a facility and the importance of communicafion within the operafional elements.
The Facility Maintenance and Operation Core provides high containment management and oversight, preventive maintenance and upkeep ofthe GNL physical plant, and specialized training for facilities personnel working in and around the BSL4 labs and associated systems. Operations and maintenance is closely coordinated with scientific program needs to ensure optimum support and maximum productivity.
|Mire, Chad E; Geisbert, Joan B; Borisevich, Viktoriya et al. (2017) Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci Transl Med 9:|
|Mire, Chad E; Cross, Robert W; Geisbert, Joan B et al. (2017) Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat Med 23:1146-1149|
|Thi, Emily P; Mire, Chad E; Lee, Amy Ch et al. (2017) siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease. J Clin Invest :|
|Satterfield, Benjamin A; Cross, Robert W; Fenton, Karla A et al. (2016) Nipah Virus C and W Proteins Contribute to Respiratory Disease in Ferrets. J Virol 90:6326-43|
|Mire, Chad E; Geisbert, Thomas W; Feldmann, Heinz et al. (2016) Ebola virus vaccines - reality or fiction? Expert Rev Vaccines 15:1421-1430|
|Agrawal, Anurodh Shankar; Tao, Xinrong; Algaissi, Abdullah et al. (2016) Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 12:2351-6|
|Thi, Emily P; Lee, Amy C H; Geisbert, Joan B et al. (2016) Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA. Nat Microbiol 1:16142|
|Mire, Chad E; Geisbert, Joan B; Agans, Krystle N et al. (2016) Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus. J Infect Dis 214:S263-S267|
|Cross, Robert W; Mire, Chad E; Branco, Luis M et al. (2016) Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antiviral Res 133:218-222|
|Olsen, Michelle E; Filone, Claire Marie; Rozelle, Dan et al. (2016) Polyamines and Hypusination Are Required for Ebolavirus Gene Expression and Replication. MBio 7:|
Showing the most recent 10 out of 54 publications